The revealing moment in Gerard Rivera’s account of RIS Rx is a piece of paperwork: the business rules for a copay card. Rivera, a pharmacist, saw an expensive mismatch. A manufacturer might cover six months of a patient’s out-of-pocket costs when two months would give the doctor enough time to secure insurance authorization. The assistance was generous. The timing was wasteful. And somewhere beyond the spreadsheet was a person trying to stay on treatment.
- RIS Rx sells manufacturers software and services that inspect where affordability spending goes.
- Its approach combines claims analysis with pharmacists who pursue corrections.
- The useful question: did lower spending preserve the patient’s access?
A budget is not a benefit
Rivera and fellow pharmacist Stephen Hom founded RIS Rx in 2020. Their experience supplied two views of the same system: the patient facing an unexpected copay, and the pharmaceutical executive overseeing a large assistance budget. The founders’ explanation is that connecting those views exposed avoidable gaps. Money allocated to affordability could be spent without delivering the relief its designers intended.
The company works in gross-to-net, the distance between a drug’s gross sales and what its manufacturer ultimately retains after deductions. Its chosen territory is patient affordability spending. Manufacturers buy the service; patients, pharmacies and support teams encounter its consequences. That creates an interesting test of success. A cheaper program is useful only if the right patient can still get the prescription.
The claim is where the argument happens
Copay assistance can collide with several kinds of insurance arrangements. Accumulators prevent manufacturer assistance from counting toward a patient’s deductible. Maximizers organize how that assistance is drawn down. Alternative funding arrangements can steer people toward manufacturer assistance channels. Then there is pharmacy misprocessing, where the claim itself needs attention. These problems arrive through different doors, but each can separate spending from its intended purpose.
RIS Rx’s September 2026 maximizer playbook offers a small, concrete illustration. The company describes reprocessing a claim that sought $3,750 and correcting it to a $125 cap. That is $3,625 on one claim, according to its account. The point is the timing: a questionable payment becomes harder to influence once the money has moved and the next prescription is already due.
$3,625 difference. A company-reported example, not an average outcome.
Six ways into the same problem
The product names read like a small department directory. Benefit Patient Solution addresses accumulator and maximizer leakage. Triple A, short for Affordability, Audit and Assurance, examines pharmacy copay claims. PatientGuard 360 watches patient assistance, free-goods and bridge programs. Precision Pay handles reimbursement for accumulator-affected patients. PreVail verifies benefits electronically. OmniCheck screens insurance eligibility and government coverage. Manufacturers can select the pieces they need.
The benefits-verification story supplies another telling detail. In a September podcast interview, RIS Rx’s Daniel Lozano describes translating the cryptic “reject code 75” into something a clinician could act on. A rejection code looks like an endpoint to someone who cannot interpret it. To someone who understands the insurance context, it can suggest a next step. Expertise changes what the same screen means.
Pay for the outcome
RIS Rx’s platform page advertises payment based on dollars saved. That makes the commercial proposition easy to understand: identify a spending problem, intervene, measure the difference. For a buyer, the hard conversation moves to measurement. Which dollars were recovered? Which were avoided? Against what baseline? Those questions belong in the buying process because a savings figure is only as useful as the method behind it.
The competitive field is real. ConnectiveRx also offers copay services and real-time claim protection through its GTN platform. IntegriChain addresses broader revenue operations, including forecasting, accruals and financial close. RIS Rx’s emphasis is the affordability transaction and the operational work surrounding it. Its pitch is especially relevant to manufacturers seeking an added control within existing programs.
Summit Partners made a growth investment in June 2025. The announcement described profitable growth and reported service to 23 manufacturers across more than 160 drug brands at that time. Product development, hiring and client services were the stated uses of the investment. The business had moved beyond a pharmacy insight into an operation that institutional capital could help expand.
The pause that exposed the work
In August 2026, RIS Rx extended Triple A with an API that flags misprocessed claims before payment. Its announcement also described a one-month monitoring pause on one program, during which misprocessed claims rose 51%. That is a company-reported observation from one program. Still, it raises the story’s most useful operational question: what happens when oversight stops?
“A real-time alert nobody follows-up on is just a faster way to watch money leave the program.”Stephen Hom, co-founder and COO
The answer requires people. RIS Rx says its pharmacists contact pharmacies, pursue corrected claims and document changes. Its fellowship, offered with Loma Linda University School of Pharmacy, gives pharmacists projects across reimbursement, operations and analytics. That is a practical way to build a workforce able to move between a clinical conversation and an operational one.
There is a less glamorous version of that culture in the recruiting materials. An HR posting lists mentorship, career development, an employer-paid base HMO plan and paid time off that increases with tenure. Those are concrete employment promises. They also fit a business whose service depends on retaining people who understand complicated workflows.
Bring the counter into the boardroom
There are dependencies behind the promise. Claims must arrive, systems must connect, permissions must be agreed and someone must resolve exceptions. RIS Rx’s security leaders describe encryption, access reviews, independent penetration testing and an annual SOC 2 Type II assessment. Handling the information is part of delivering the intervention.
A September interview with commercial solutions executive Dan Bench applies the same thinking to the annual insurance reset. Segment patients before reverification, prepare support capacity and watch claims for people who need outreach. The calendar gives the team advance notice. Waiting for the confused patient to call wastes that advantage.
The lesson another business can copy is modest and demanding: put the person who understands the failure beside the person who can change the process. Give both a way to see whether the correction worked. For RIS Rx, the final check reaches beyond a cleaner spending report. It returns to the counter, where a patient finds out what the prescription will actually cost.